Skip to main content

Table 2 Primary and secondary treatment outcomes according to assigned treatment.

From: Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

  Placebo
(n = 6)
Ascorbic acid
(n = 5)
  
  Change Change Difference Pvalue
Median nerve MNCV (m/s)a -0.8 (0.9) 0.5 (1.5) 1.3 (-0.3-3.0) 0.11
Median nerve minimal F response latency (ms)a 3.5 (8.0)* -5.6 (4.4) -9.1 (-18.5-0.3) 0.06
CMAP amplitude abductor pollicis brevis muscle (mV)a -0.02 (0.9) -0.2 (0.8) -0.1 (-1.3 -1.1) 0.79
Three point grip (N)a -3.0 (9.2) 3.4 (9.0) 6.4 (-6.1-18.9) 0.28
Foot dorsiflexors (N)a -5.1 (17.6) 0.6 (15.6) 5.6 (-17.3-28.6) 0.59
ISSb 0 (-4-1) -2 (-2-1) -2 (-2-2) 0.30
CMTNSb 1 (-5-4) -2 (-3-1) -3 (-6-3) 0.14
ODSSb 0 (0-1) 0 (-2-0) 0 (-2-0) 0.18
ALDSa 1.0 (3.7) 0.3 (0.4) -0.6 (-4.5-3.2) 0.30
Nine hole peg test (s)a -3.5 (2.8) -2.0 (1.8) 1.5 (-1.8-4.8) 0.32
50 m walking (s)a -0.6 (1.9) -0.9 (1.8) -0.3 (-2.9-2.2) 0.77
  1. Change = a mean (standard deviation) or b median (range) change scores from baseline to final follow-up. Difference = difference in a mean or b median change scores (95% confidence interval) of the patients receiving ascorbic acid and those receiving placebo. P-value = P-value for a the unpaired t test (equal variances assumed) or b the Mann-Whitney U test. * n = 5
  2. Abbreviations: ALDS = Academic Medical Centre linear disability score; CMAP = compound muscle action potential; CMTNS = Charcot-Marie-Tooth neuropathy score; ISS = inflammatory neuropathy cause and treatment sensory sum score; MNCV = motor nerve conduction velocity; ODSS = overall disability sum score